ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-33L15527
Home | Market Reports | Health| Health Conditions| Cancer
Global Kirsten Rat Sarcoma Viral Oncogene Homolog KRAS Inhibitors Market Research Report 2023
BUY CHAPTERS

Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Research Report 2025

Code: QYRE-Auto-33L15527
Report
May 2025
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amgen Inc
Mirati Therapeutics
Novartis
Genentech Inc
Revolution Medicines
Cardiff Oncology
BridgeBio Pharma
Deciphera Pharmaceuticals
InventisBio
Gritstone Bio
Verastem Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
Elicio Therapeutics
D3 Bio

Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market

The global market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in Retail Pharmacy is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors include Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors.
The Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Report

Report Metric Details
Report Name Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market report?

Ans: The main players in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market are Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio

What are the Application segmentation covered in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market report?

Ans: The Applications covered in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market report are Retail Pharmacy, Hospital Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market report?

Ans: The Types covered in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market report are Direct Inhibitors, Signal transduction inhibitors

Recommended Reports

Cancer Therapeutics

Oncogene Targeting

Inhibitor Drugs Market

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Direct Inhibitors
1.2.3 Signal transduction inhibitors
1.3 Market by Application
1.3.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Retail Pharmacy
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Perspective (2020-2031)
2.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Growth Trends by Region
2.2.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Historic Market Size by Region (2020-2025)
2.2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Region (2026-2031)
2.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Dynamics
2.3.1 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Industry Trends
2.3.2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Drivers
2.3.3 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Challenges
2.3.4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players by Revenue
3.1.1 Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players by Revenue (2020-2025)
3.1.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Players (2020-2025)
3.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue
3.4 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Concentration Ratio
3.4.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in 2024
3.5 Global Key Players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Head office and Area Served
3.6 Global Key Players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, Product and Application
3.7 Global Key Players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Breakdown Data by Type
4.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Historic Market Size by Type (2020-2025)
4.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Type (2026-2031)
5 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Breakdown Data by Application
5.1 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Historic Market Size by Application (2020-2025)
5.2 Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2020-2031)
6.2 North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2020-2025)
6.4 North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2020-2031)
7.2 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2020-2025)
7.4 Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2020-2031)
8.2 Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2020-2025)
8.4 Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2020-2031)
9.2 Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2020-2025)
9.4 Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (2020-2031)
10.2 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2020-2025)
10.4 Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.1.4 Amgen Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.1.5 Amgen Recent Development
11.2 Mirati Therapeutics
11.2.1 Mirati Therapeutics Company Details
11.2.2 Mirati Therapeutics Business Overview
11.2.3 Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.2.4 Mirati Therapeutics Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.2.5 Mirati Therapeutics Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.3.4 Novartis Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.3.5 Novartis Recent Development
11.4 Genentech
11.4.1 Genentech Company Details
11.4.2 Genentech Business Overview
11.4.3 Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.4.4 Genentech Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.4.5 Genentech Recent Development
11.5 Verastem Oncology
11.5.1 Verastem Oncology Company Details
11.5.2 Verastem Oncology Business Overview
11.5.3 Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.5.4 Verastem Oncology Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.5.5 Verastem Oncology Recent Development
11.6 Revolution Medicines
11.6.1 Revolution Medicines Company Details
11.6.2 Revolution Medicines Business Overview
11.6.3 Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.6.4 Revolution Medicines Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.6.5 Revolution Medicines Recent Development
11.7 Cardiff Oncology
11.7.1 Cardiff Oncology Company Details
11.7.2 Cardiff Oncology Business Overview
11.7.3 Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.7.4 Cardiff Oncology Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.7.5 Cardiff Oncology Recent Development
11.8 Immuneering Corporation
11.8.1 Immuneering Corporation Company Details
11.8.2 Immuneering Corporation Business Overview
11.8.3 Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.8.4 Immuneering Corporation Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.8.5 Immuneering Corporation Recent Development
11.9 Jacobio Pharmaceuticals
11.9.1 Jacobio Pharmaceuticals Company Details
11.9.2 Jacobio Pharmaceuticals Business Overview
11.9.3 Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.9.4 Jacobio Pharmaceuticals Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.9.5 Jacobio Pharmaceuticals Recent Development
11.10 BridgeBio Pharma
11.10.1 BridgeBio Pharma Company Details
11.10.2 BridgeBio Pharma Business Overview
11.10.3 BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.10.4 BridgeBio Pharma Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.10.5 BridgeBio Pharma Recent Development
11.11 Deciphera Pharmaceuticals
11.11.1 Deciphera Pharmaceuticals Company Details
11.11.2 Deciphera Pharmaceuticals Business Overview
11.11.3 Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.11.4 Deciphera Pharmaceuticals Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.11.5 Deciphera Pharmaceuticals Recent Development
11.12 Elicio Therapeutics
11.12.1 Elicio Therapeutics Company Details
11.12.2 Elicio Therapeutics Business Overview
11.12.3 Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.12.4 Elicio Therapeutics Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.12.5 Elicio Therapeutics Recent Development
11.13 InventisBio
11.13.1 InventisBio Company Details
11.13.2 InventisBio Business Overview
11.13.3 InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.13.4 InventisBio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.13.5 InventisBio Recent Development
11.14 Gritstone Bio
11.14.1 Gritstone Bio Company Details
11.14.2 Gritstone Bio Business Overview
11.14.3 Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.14.4 Gritstone Bio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.14.5 Gritstone Bio Recent Development
11.15 D3 Bio
11.15.1 D3 Bio Company Details
11.15.2 D3 Bio Business Overview
11.15.3 D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Introduction
11.15.4 D3 Bio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
11.15.5 D3 Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Amgen Inc
Mirati Therapeutics
Novartis
Genentech Inc
Revolution Medicines
Cardiff Oncology
BridgeBio Pharma
Deciphera Pharmaceuticals
InventisBio
Gritstone Bio
Verastem Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
Elicio Therapeutics
D3 Bio
List of Tables
 Table 1. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Direct Inhibitors
 Table 3. Key Players of Signal transduction inhibitors
 Table 4. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Region (2020-2025)
 Table 8. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Region (2026-2031)
 Table 10. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Trends
 Table 11. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Drivers
 Table 12. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Challenges
 Table 13. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Restraints
 Table 14. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Players (2020-2025)
 Table 16. Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors as of 2024)
 Table 17. Ranking of Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, Headquarters and Area Served
 Table 20. Global Key Players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, Product and Application
 Table 21. Global Key Players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Type (2020-2025)
 Table 25. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Type (2026-2031)
 Table 27. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Application (2020-2025)
 Table 29. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue Market Share by Application (2026-2031)
 Table 31. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Amgen Company Details
 Table 47. Amgen Business Overview
 Table 48. Amgen Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 49. Amgen Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 50. Amgen Recent Development
 Table 51. Mirati Therapeutics Company Details
 Table 52. Mirati Therapeutics Business Overview
 Table 53. Mirati Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 54. Mirati Therapeutics Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 55. Mirati Therapeutics Recent Development
 Table 56. Novartis Company Details
 Table 57. Novartis Business Overview
 Table 58. Novartis Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 59. Novartis Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 60. Novartis Recent Development
 Table 61. Genentech Company Details
 Table 62. Genentech Business Overview
 Table 63. Genentech Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 64. Genentech Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 65. Genentech Recent Development
 Table 66. Verastem Oncology Company Details
 Table 67. Verastem Oncology Business Overview
 Table 68. Verastem Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 69. Verastem Oncology Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 70. Verastem Oncology Recent Development
 Table 71. Revolution Medicines Company Details
 Table 72. Revolution Medicines Business Overview
 Table 73. Revolution Medicines Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 74. Revolution Medicines Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 75. Revolution Medicines Recent Development
 Table 76. Cardiff Oncology Company Details
 Table 77. Cardiff Oncology Business Overview
 Table 78. Cardiff Oncology Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 79. Cardiff Oncology Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 80. Cardiff Oncology Recent Development
 Table 81. Immuneering Corporation Company Details
 Table 82. Immuneering Corporation Business Overview
 Table 83. Immuneering Corporation Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 84. Immuneering Corporation Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 85. Immuneering Corporation Recent Development
 Table 86. Jacobio Pharmaceuticals Company Details
 Table 87. Jacobio Pharmaceuticals Business Overview
 Table 88. Jacobio Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 89. Jacobio Pharmaceuticals Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 90. Jacobio Pharmaceuticals Recent Development
 Table 91. BridgeBio Pharma Company Details
 Table 92. BridgeBio Pharma Business Overview
 Table 93. BridgeBio Pharma Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 94. BridgeBio Pharma Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 95. BridgeBio Pharma Recent Development
 Table 96. Deciphera Pharmaceuticals Company Details
 Table 97. Deciphera Pharmaceuticals Business Overview
 Table 98. Deciphera Pharmaceuticals Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 99. Deciphera Pharmaceuticals Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 100. Deciphera Pharmaceuticals Recent Development
 Table 101. Elicio Therapeutics Company Details
 Table 102. Elicio Therapeutics Business Overview
 Table 103. Elicio Therapeutics Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 104. Elicio Therapeutics Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 105. Elicio Therapeutics Recent Development
 Table 106. InventisBio Company Details
 Table 107. InventisBio Business Overview
 Table 108. InventisBio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 109. InventisBio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 110. InventisBio Recent Development
 Table 111. Gritstone Bio Company Details
 Table 112. Gritstone Bio Business Overview
 Table 113. Gritstone Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 114. Gritstone Bio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 115. Gritstone Bio Recent Development
 Table 116. D3 Bio Company Details
 Table 117. D3 Bio Business Overview
 Table 118. D3 Bio Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Product
 Table 119. D3 Bio Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025) & (US$ Million)
 Table 120. D3 Bio Recent Development
 Table 121. Research Programs/Design for This Report
 Table 122. Key Data Information from Secondary Sources
 Table 123. Key Data Information from Primary Sources
 Table 124. Authors List of This Report


List of Figures
 Figure 1. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Picture
 Figure 2. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Type: 2024 VS 2031
 Figure 4. Direct Inhibitors Features
 Figure 5. Signal transduction inhibitors Features
 Figure 6. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Application: 2024 VS 2031
 Figure 8. Retail Pharmacy Case Studies
 Figure 9. Hospital Pharmacy Case Studies
 Figure 10. Online Pharmacy Case Studies
 Figure 11. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Report Years Considered
 Figure 12. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Region: 2024 VS 2031
 Figure 15. Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Players in 2024
 Figure 16. Global Top Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Revenue in 2024
 Figure 18. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Country (2020-2031)
 Figure 20. United States Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Country (2020-2031)
 Figure 24. Germany Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Region (2020-2031)
 Figure 32. China Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Country (2020-2031)
 Figure 40. Mexico Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Share by Country (2020-2031)
 Figure 44. Turkey Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Amgen Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 48. Mirati Therapeutics Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 49. Novartis Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 50. Genentech Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 51. Verastem Oncology Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 52. Revolution Medicines Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 53. Cardiff Oncology Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 54. Immuneering Corporation Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 55. Jacobio Pharmaceuticals Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 56. BridgeBio Pharma Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 57. Deciphera Pharmaceuticals Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 58. Elicio Therapeutics Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 59. InventisBio Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 60. Gritstone Bio Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 61. D3 Bio Revenue Growth Rate in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Business (2020-2025)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Global KRAS Inhibitor Market Research Report 2024
Global KRAS ELISA Kits Market Research Report 2024
Global HER2 Inhibitors Market Research Report 2024
Global KRAS G12C Inhibitors Market Research Report 2024
Global Salirasib Market Research Report 2024
Global Tyrosine Kinase Inhibitor Market Research Report 2024
Global Targeted Drug ROS1 Inhibitors for NSCLC Market Research Report 2024
Global KRAS Antibody Market Research Report 2024
Global Cancer mTOR Inhibitors Market Research Report 2024
Global Janus Kinases Inhibitor Drugs Market Research Report 2024
Global Targeted Drug HER2 Inhibitors for NSCLC Market Research Report 2024
Global PARP Inhibitors for Breast Cancer Market Research Report 2024
Global Mitogen Activated Protein Kinase MAPK Inhibitors Therapeutics Market Research Report 2024
Cancer Growth Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cancer Tubulin Inhibitors Market Research Report 2024
Global Targeted Drug MEK Inhibitors for NSCLC Market Research Report 2024
Global Generation III EGFR Inhibitors Market Research Report 2024
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Research Report 2024
Global Cancer CDK Inhibitors Market Research Report 2025
Global CDK4 6 Inhibitors for Breast Cancer Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions